Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy.

摘要: In Asian countries, age-related macular degeneration (AMD), specifically wet AMD or choroidal neovascularisation (CNV), is an important cause of blindness and visual handicap. Vascular endothelial growth factors (VEGF) play integral role in the development CNV thus provide therapeutic target. Current treatment paradigms for neovascular recognise place photodynamic therapy (PDT) management this condition. However, combination targeting different pathways to produce a synergistic effect may result improved outcomes reduced duration treatment. Anti-VEGF has greatly patients with CNV, growing body evidence supports these agents as monotherapy PDT. particular, anti-VEGF be first-line option certain types subfoveal myopic well classic occult juxtafoveal CNV. The implementation evidence-based medicine into current clinical practice paramount improving patient care. authors, who are also members Singapore Medical Retina Advisory Board, outline consensus points recommended algorithms based on currently available knowledge structured approach